|
1) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266
|
|
|
|
2) 日本腎臓学会. CKD診療ガイド2009. 東京: 東京医学社; 2009
|
|
|
|
|
|
3) 日本腎臓学会. エビデンスに基づいたCKD診療ガイドライン2009. 2009
|
|
|
|
|
|
4) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン2009. 日本高血圧学会; 2009
|
|
|
|
|
|
5) Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005; 28: 385-407
|
|
|
|
|
6) Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36: 646-61
|
|
|
|
|
|
7) Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334: 13-8
|
|
|
|
|
|
8) Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 29: 641-50
|
|
|
|
|
|
9) 日本腎臓学会, 日本高血圧学会. CKD診療ガイド―高血圧編―. 2008
|
|
|
|
|
|
10) Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154-69
|
|
|
|
|
|
11) de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004; 110: 921-7
|
|
|
|
|
|
12) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-9
|
|
|
|
|
|
13) de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004; 65: 2309-20
|
|
|
|
|
|
14) Kaplan NM, Flynn JT. Treatment of hypertension: drug therapy. In: Clinical Hypertension. Philadelphia: Lippincott Williams & Wilkins; 2006. p.217-310
|
|
|
|
|
|
15) PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-41
|
|
|
|
|
|
16) Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes？ Arch Intern Med. 2003; 163: 2557-60
|
|
|
|
|
|
17) Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000; 35: 1025-30
|
|
|
|
|
|
18) Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-28
|
|
|
|
|
|
19) Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010; 56: 77-85
|
|
|
|
|
|
20) Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375: 1173-81
|
|
|
|
|
|
21) Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-9
|
|
|
|
|
|
22) ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-97
|
|
|
|
|
|
23) Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007; 25: 951-8
|
|
|
|
|
|
24) Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-59
|
|
|
|
|
|
25) Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547-53
|
|
|
|
|
|
26) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997; 349: 1857-63
|
|
|
|
|
|
27) Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target？Nat Rev Nephrol. 2009; 5: 436-7
|
|
|
|
|